SecBot SecBot

KRRO

Korro Bio, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001703647 Biotech & Drug Discovery
$13.30 +1.28 (+10.65%)
Oct 27 4:00 PM ET · prev $12.02
Market cap
$176.4M
Micro cap
Consensus
Buy
89% Buy or better · 18 analysts
Median target
$21.50
+62% · range $10.00–30.00
Next earnings
Nov 18
in 22 days · EPS est. −$1.26
1 year
−66.8%
from $40.08 · Oct 28
30 days
+39.9%
from $9.51
52-week range
$5.28–40.91
−67% from high · low Dec 2
Avg volume 20D
197.7K
shares / day
Short interest
1.73M
≈11.8% of shares · +3.4%
Days to cover
9.6
at average volume
Insider net
−$4.7M
1 buyer · 6 sellers · since May 26
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 9 reports · 90 days
Balance 0 bearish · 3 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 4/9 ·Next Earnings date, Nov 18, 2026
Strongest BULLISH Korro Bio reported preclinical data for KRRO-111, its RNA-editing candidate for Alpha-1 Antitrypsin…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $963.6K at an average $11.14. 6 insiders sold $5.7M. Price is 19% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 31 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    16 of 18 rate it Buy or better. Median target $21.50 (+62%).

  • EstimatesFLAT

    Current-quarter EPS estimate −$1.269 → −$1.262 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.4% to 1.73M shares. 9.6 days to cover, ≈11.8% of shares.

  • TrendRANGE

    17% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD817,621$10.8M
ADAGE CAPITAL PARTNERS GP, L.L.C.DOUBLED540,968$7.1M
VANGUARD CAPITAL MANAGEMENT LLCADD454,778$6.0M
GEODE CAPITAL MANAGEMENT, LLCADD296,870$3.9M
STATE STREET CORPADD232,587$3.1M
VANGUARD PORTFOLIO MANAGEMENT LLCADD223,551$2.9M
JPMORGAN CHASE & COADD124,726$1.6M
MILLENNIUM MANAGEMENT LLCADD118,434$1.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 89% rate it Buy or better
Strong Buy5Buy11Hold2Sell0Strong Sell0
12-month targets · 10 analysts

Price is inside the target range. Median implies +62%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 6, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 20, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
May 19, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
May 18, 2026Citigroup
INITIATE
INITIATEBuy

Insider ledger

Form 4
$963.6K
bought · 1 insider
$5.7M
sold · 6 insiders
+19.4%
vs their $11.14 cost
DateInsiderTypeValue
Oct 26, 2026
Lynx1 Capital Management LP
10%+ Owner
BUY$295.1K
Oct 23, 2026
Lynx1 Capital Management LP
10%+ Owner
BUY$30.4K
Oct 22, 2026
Lynx1 Capital Management LP
10%+ Owner
BUY$441.5K
Oct 22, 2026
Lynx1 Capital Management LP
10%+ Owner
BUY$117.8K
Sep 14, 2026
FORMELA JEAN FRANCOIS
Director
SELL$450.3K
Sep 14, 2026
FORMELA JEAN FRANCOIS
Director
SELL$93.2K
Sep 11, 2026
Dolan Oliver
Senior Vice President, Finance
SELL$68.58
Sep 11, 2026
FORMELA JEAN FRANCOIS
Director
SELL$24.5K

Earnings setup

Estimates
Nov 18
reports in 22 days
−$1.26
EPS estimate, this quarter
+1%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.26-$2.04–-$0.93-1.1%$187.5K
Next Q-$1.36-$2.44–-$0.74-0.4%$187.5K
Current FY-$5.23-$7.25–-$4.22-1.1%$375.0K
Next FY-$4.42-$5.04–-$3.55+0.8%$587.5K

Short side

FINRA· Oct 15, 2026
1,732,855
shares short
+3.4%
vs prior settlement
9.6
days to cover
≈11.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 27, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 26, 2026 SEC
Lynx1 Capital Management, a 10% owner of Korro Bio, purchased 12,175 shares at $9.68 for $118K in an open-market…
INSIDER-BUY — Impact 5/10
Oct 26, 2026 Insider
Lynx1 Capital Management LP bought 25,124 shares
10%+ Owner @ $11.75 ($295.1K)
Oct 23, 2026 Insider
Lynx1 Capital Management LP bought 2,510 shares
10%+ Owner @ $12.11 ($30.4K)
Oct 22, 2026 SEC
Korro Bio reported preclinical data for KRRO-111, its RNA-editing candidate for Alpha-1 Antitrypsin Deficiency (AATD)…
8-K — Impact 6/10
Oct 22, 2026 Insider
Lynx1 Capital Management LP bought 40,000 shares
10%+ Owner @ $11.04 ($441.5K)
Oct 16, 2026 Press
Korro Bio granted non-statutory stock options to two new employees as an inducement to employment, covering 4,000…
Impact 2/10
Oct 16, 2026 Regulatory
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinic
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 18, 2026
Earnings date
KRRO Q3 2026 Earnings Scheduled — 2026-11-18
Recent
Oct 16, 2026
Regulatory
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a…
Oct 5, 2026
FDA
Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging…
Aug 27, 2026
Press release
Korro to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel…
Aug 14, 2026
Press release
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel…
Jul 10, 2026
Press release
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 10, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a biopharmaceutical company leveraging a novel…

SecBot reports

17 filings · 3 press releases · 6 bullish · 2 bearish · 9 neutral
All KRRO filing & press-release reports (20)